Scope of this summary
Adults鈥攁lmost always over age 50鈥攚ith new bilateral shoulder or hip-girdle pain and prolonged morning stiffness suggesting polymyalgia rheumatica. The 2015 EULAR/ACR recommendations remain the ACR collaborative management source; a July 2026 EULAR update is listed for current evidence but requires explicit US applicability review.
The Bottom Line
- Confirm a compatible syndrome with raised inflammatory markers when typical, but actively exclude rheumatoid arthritis, myopathy, endocrine disease, infection, malignancy and medication effects before committing to prolonged steroids.
- Screen every suspected PMR patient for giant cell arteritis symptoms鈥攏ew headache, scalp tenderness, jaw or tongue claudication, visual symptoms, constitutional illness and limb claudication鈥攂ecause treatment urgency differs.
- Use individualized oral glucocorticoid treatment with the lowest dose that achieves remission, followed by a structured taper based on symptoms, markers and adverse effects rather than an abrupt fixed schedule.
- Consider early rheumatology referral for atypical presentation, low inflammatory markers, poor steroid response, frequent relapse, high toxicity risk or a need for steroid-sparing treatment.
- Prevent and monitor glucocorticoid harms from the start, including osteoporosis, diabetes, hypertension, infection, cataract, mood and adrenal suppression.
Practical clinical workflow
1
Document age, onset, shoulder and hip stiffness, function, headache, jaw symptoms, vision, fever, weight, weakness and medication exposure; examine joints, proximal power, pulses and temporal arteries.
2
Obtain ESR or CRP, blood count, metabolic and liver panels, thyroid testing, creatine kinase and additional tests from the differential; use ultrasound or other imaging when it resolves uncertainty.
3
When the syndrome is typical and GCA is not suspected, start source-aligned glucocorticoid treatment, explain expected response and arrange early reassessment rather than using response as the sole diagnostic test.
4
Taper only after remission, track relapse and cumulative steroid exposure and reconsider the diagnosis if pain or markers do not behave as expected.
5
Use rheumatology input for methotrexate, sarilumab or another steroid-sparing strategy, applying the current FDA indication and monitoring rather than extrapolating from class effects.
Safety boundaries and escalation
- Any new visual loss, diplopia, amaurosis fugax, jaw claudication or convincing GCA syndrome requires immediate high-dose treatment and urgent specialist assessment; testing must not delay vision protection.
- Objective proximal weakness, very high creatine kinase, fever or a focal painful joint suggests another disease and should not be masked with escalating steroids.
- Long-term glucocorticoids require fracture-risk prevention, vaccination, infection counseling and metabolic monitoring; adrenal suppression can make sudden cessation dangerous.
- The July 2026 EULAR update is not an ACR-endorsed US guideline; this summary therefore keeps the source roles explicit and does not silently present an EULAR-only change as ACR guidance.
Localization
US care should use rheumatology judgment, current FDA sarilumab labeling and local access while acknowledging that the latest 2026 evidence update is European.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- European League Against Rheumatism and American College of Rheumatology2015 recommendations for the management of polymyalgia rheumaticaDOI 10.1002/art.39333 路 published 2015-10-01 路 accessed 2026-08-20view source
- European Alliance of Associations for Rheumatology2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitisDOI 10.1016/j.ard.2026.06.009 路 published online 21 July 2026; requires US clinical applicability review 路 published 2026-07-21 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.